Pharma Industry Report

7/24/2019 Pharma Industry Report

1/24

INDIAN PHARMACEUTICAL INDUSTRY

GROUP 9: EQUILIBRIUMMEMBERS: POOJA VERMA(1421337)

VINEET RAINA(1421332)

SAYON DAS(142132!)

DISHANT BANSAL(14213"9)

BHAVANA #ONETI(1421341)

#ARTHI# ESH$ARAN(142131%)


2/24

INTRODUCTION TO

PHARMACEUTICAL INDUSTRY IN

INDIA

1930:First pharmaceutical company called Bengal Chemicals and pharmaceutical works ws started

which exists even today as government owned drug manufacturers.

1970: Patent act was introduced which saw a major breakthrough in pharma industry and gave

boost to the industry.

1980: he industry values !"# million compared to !"# billion in "$%&.

1992: 'ith liberali(ation )ndian pharma industry detached from the then included in manufacturing

industry and started expanding in )ndia and abroad attracting foreign investments.

*ccording to )ndian Brand e+uity foundation the )ndian pharma industry is growing at a C*,- of

%.& / between "$%"0"$%1 2forecasted3.

)n terms of volume )ndia is %.&/ in value standing at %&thposition and %$/ in terms of volume

standing at 4rdposition.

oday )ndian companies are investing heavily on -56 7 reengineering7 increase exports in more

than "$$ countries7 penetrating in the )ndian market and expanding abroad. his has led

Pharmaceutical industry to be key drivers of economy.


3/24

P&'()'

A*+,-./&'()'*.0+,*

'1,23(.4,.2+56B

017 4(035

B('24.4 G.2.(,*

89()01'+,925

C&(92,*

C'(4,9-'5*01'(2.0(9193,*'1'

2+,:4,';.+.53'5+(

9 ,2+.5+,2'1

A*0+.

'2+,:,2


4/24


5/24

+RO,TH IN PHARMACEUTICAL IN INDIA

2""! 2""9 2"1" 2"11 2"12 2"13 2"14 2"1% 2"1?"

%

1"

1%

2"

2%

3"

3%

4"

1" 11

141?

17

21

2%

3"

3?

Outlook for Indian pharmaceutical industry by et !evenue"#S$ billion%

Source: #&& I'(%#' or%-%' c"e$%)t) . (%)tr%/utor) (e! o !"#r$#ceut%c#&) !''%'- co$$%))%o'

re!ort %/eor-

Current growth outlook C*,- is at %.&/ from "$$; to "$%1. Current value of )ndian pharmaceutical

industry is "# billion which is expected to grow to 41 billion.

T"%) %) re)u&te( (ue to 4#r%ou) re#)o') )uc" #):

-)< )= P?


6/24

HHI

M#r@et S"#re O Co$!#'%e) %' o' /#)%) o Net Re4e'ue

Sun &harma '() 1)(*)

+*'

21*(,

,-

$r !eddy 7@! 13@?9?22 1!7@%!??.upin ?@4 11@237

93

12?@29

1/ipla %@2 9@13"!

17

!3@371

!1urobindo &harma 3@? ?@3213

3%

39@9%9

27/adila ealth 2@4 4@2142

23

17@7%9

?!Ipca .abs 2@1 3@?!74

4%

13@%97

2%ubilant .ife 2 3@%11!

%3

12@333

11orrent &harma 1@! 3@1?"?

?7

9@9!9!

174la5oSmith6line 1@? 2@!"94

!2

7@!931

!97ockhardt 1@? 2@!"94

!2

7@!931

!9Sun &harma dv 1@%? 2@7392

4%

7@%"34

?34lenmark 1@%4 2@7"41

2?

7@3123

$ivis .abs 1@41 2@47%!

%?

?@129!

?3Orchid chemical 1@2? 2@2124

?7

4@!9%"

11Sano8 India 1@2 2@1"71

12

4@4399

19ectar .ife 1 1@7%%9

2?

3@"!32

77lembic &harma "@9 1@%!"3

34

2@4974

%4

&iramal 9nter "@9 1@%!"334

2@4974%4

9lder &harma "@!2 1@439!

?

2@"731

9%:anta &harma "@7 1@2291

4!

1@%1"!

"?Ind;Ser "@7 1@2291

4!

1@%1"!

"?#nichem .abs "@?? 1@1%!9

11

1@343"

7%%?@9% 1"" 772@"4

92

C ',.5


7/24

B $#r@et )"#re out o 100

T"e )co!e o t"%) #'#&*)%) %) !"#r$# co$!#'%e) %t" 'et re4e'ue -re#ter t"#' R) 1000 cr or 51=0

$%&&%o'

he op # companies command 4"/ of the market share

Companies with net revenue greater than -s %$$$ cr or ! %1$ million command a share of #1.# / of market

in pharmaceutical industry.

T"e HHI %) 7720


8/24

A


9/24

his table shows players in pharmaceutical industry of )ndia by =et -evenue in the )ndian market which

have =et ales above %$$$ crore rupees which is e+uivalent to !%1$ million.

*s of H% F"$%& un Pharmaceuticals is at the top in =et -evenue at ! ".% billion which increased

significantly recently due to the ac+uisition of -anbaxy. 6r -eddys 9aboratories is second with =et -evenue

amounting to ! " billion followed by 9upin with ! %.1 billion.

*mong this list Cipla7 un Pharmaceuticals and 6r -eddys 9aboratories is listed in the


10/24

2ource: www.moneycontrol.com3

he above able shows key players in the pharmaceutical markets ranked on the basis of market

capitalisation.

un pharmaceutical based on market capitalisation is at the top with ! " billion followed by 9upin with !;.4

billion and 6r -eddys Pharmaceutical at 5! .; billion while global giants as ,laxomith8line with ! 4.&

billion and Pfi(er with ! 1;& million.

72>

19>

9>

!eveneue share of Indian &harmaceutical sub;se?ments in FY2013

G..(,* ).4,*,.

O-.( +&. *0+.( ).4,*,.

P'+.+.4 4(035


re!ort %/eor-

72of market share 2in revenue3 is generic drug which is highest7 currently at 5183 /%&&%o'. >ver the

counter medicine at 192revenue3 and patented drug at 9

1!>

12>

11>

9>!>

7>

3%>

Market se?ment "by revenue value% in FY2013

A+,,


11/24

178anti0infective7 123 cardiac7 11gastro intestinal7 89vitaminsImineralsInutrients

8respiratory7 7pain 5 analgesics7 3


12/24

2""! 2""9 2"1" 2"11 2"12 2"13 2"14 2"1% 2"1?

?@9 !@1 1" 11@3 12@? 1%@1 1!@2 21@! 2?@1

"@! "@9 1@1 1@3 1@% 1@! 2@2 2@7 3@3

Share of ?eneric @ patented pharma in Abillion

G..(,* P'+.+.

Curre't&* %' !re)cr%/e( (ru-) -e'er%c) co$$#'() 5182 /%&&%o' "ere#) !#te'te( "o&() 522 /%&&%o'

PER CAPITA SALES IN PHARMACEUTICAL INDUSTRY

2"1" 2"11 2"12 2"13 2"14 2"1% 2"1?"

%

1"

1%

2"

2%

3"

1113

141?

19

23

27

&er /apita Sales of &harmaceutical "#S$%


re!ort %/eor-

Per capita sales in current year are !% which is expected to grow at !" by "$%1 at a C*,- at %1.4/. his

is primarily dependent at per capita income.


13/24

Tr#(e o I'(%#' !"#r$#ceut%c#& %'(u)tr*

8Y"? 8Y"7 8Y"! 8Y"9 8Y1" 8Y11 8Y12 8Y13"

2

4

?

!

1"

12

3rade $ata Of Indian &harmaceutical industry "#S$% billion

"#S$% billion


14/24

S0/&'()

'

(';'=

B3@2;,,9

A*C0,(.5

T9((.+/&'()'

.4.(B

321@?),,,9

A*C0,(.5

L0/, G(,)A*C0,(

.5

8DI B1";,,,9


re!ort %/eor-

?inistry of commerce targets to exports "# billion worth of pharmaceuticals by "$%1. )ndian drugs areexported to more than "$$ countries in the world. )ndia is the largest producer of generic drug marketaccounting for %$/ in term of volumes.

)n terms of value exports have increased with a C*,- of "1.%/.


15/24

MANU?ACTURIN+

I'(%# "#) t"e r-e)t 'u$/er o US ?DA #!!ro4e( $#'u#ctur%'- !'t) out)%(e US #t 6


16/24

,HO APPROED MANU?ACTURIN+ PLANTS Y STATES


17/24

I*. < *50. ,@. ' *50.5 ';,,+= + /'= ,5 ' -',';. , .' . +&' E0/.@ L';0 *5+ ,5 %%> *&.'/. +&'

USA ' E0/.@ T&. *5+ < 5.++, 0/ ' /0*+, /'+ , I,' ,5%"> . +&' E0/. ' USA@ C5+ .*,.*= ,5 +&. . < +&. *0*,'.'5


19/24

$9M$ $ S#&&.Y I /S9 OF .IF9 SEI4 $!#4

I *'5. < ,


20/24

S,OT ANALYSIS/#S9S FO! 4!O7 $ !9SO O IE9S I I$I

&!M/9#I/. M!69


21/24

/ost 9cient3alent =ase

L';90( *95+ ,5 %%>*&.'/.( +&' USA '4

E0(9/. &,*& ,5 '

0*('+,-. 9//0(+0,+=


22/24

!u ra l penet ra t ion

I n Ind ia *0 G o f ru ra lm arket i s un tap p ed as it i s? r o < i n ? a t a r a t e o f 2 0 G (hu s C th i s p ro v id es Ind ian

/ o m p a n ie s a m p leo p p o r tun i ti es to e5 p lo i t

a n d p e n e t r a te t h eu n t a p p e d m a r k e t(

M / s a n d I n d ia nc o m p a n i e s h a v e to o H e rd iHrent ia ted p ro d uc ts ino rd er to p en et ra te ru ra lp o p u l a t io n < h i ch m o s t lyl ives b e lo < = &. A 2 d ay(

& r o d u c t p a t e n tI n th e u ( s a n d e u r o p e f ro m

2 0 1 2 ; 2 0 1 , m a n y ? e n e r i cm ed ic ine p a tent < i ll

e5 p i re ( h i s lead s am p leo p p o r tun i ty f o r i nd ian

c o m p a n y t o e 5 p l o it a n din t r o d u c e c h e a p e r

a l ternat ives es pec ia lly in? e n e r i c d ru ? m a r k e t

.I festy le$ e m o ? r a p h i c s

I,' P /0 '+ , 5 ,


23/24

To! co$!#'%e) o4er4%e

un Pharma was set up in %;47 with compactmanufacturing facility for tablets and capsules.

)t set up its first *P) plant at Panoli in %#.oday7 it has "1 manufacturing facilities across four

continents and employs more than %&$$$ people.

>ver $/ of its sales come from international markets

)ts revenue increased from !4$.1 million in "$$ and!".% billion with C*,- of ".&/.

ource: www.ibef.org

6r -eddys began as an *P) manufacturer in %;&.

)t has integrated in 4 segments: Pharmaceuticalservices 5 *ctive ingredients7 global generics.

)t accesses emerging market with partnership with,8.

)t revenues increased from !%.# billion in F$ to!".% billion in "$%& at Cagr of %&.& /.

,lobal generics compromised %/ of its revenues.

ource: www.ibef.org


24/24

B)B9)>,-*PA

%/eor-

$e(%'(%#co$

"tt!:'c/%'&$'%"-o4

www.pharmaceuticals.gov.in/

Economic Times (august edition 2014)
http://www.ibef.org/http://www.medindia.com/http://www.ncbi.nlm.nih.gov/http://www.pharmaceuticals.gov.in/http://www.ibef.org/http://www.medindia.com/http://www.ncbi.nlm.nih.gov/http://www.pharmaceuticals.gov.in/

Pharma Industry Report

Documents

Transcript of Pharma Industry Report